Literature DB >> 22527845

Low docosahexaenoic acid content in plasma phospholipids is associated with increased non-alcoholic fatty liver disease in China.

Ju-Sheng Zheng1, Amei Xu, Tao Huang, Xiaomei Yu, Duo Li.   

Abstract

A large proportion of the Chinese population is now at risk of non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the relationship between plasma phospholipids (PL) fatty acids and the risk of NAFLD. One hundred NAFLD patients and 100 healthy subjects were recruited in Hangzhou, China. Plasma PL and selected biochemical and hematological parameters were analyzed by using standard methods. Stepwise logistic regression was used to identify independent risk factors of NAFLD. Plasma PL total saturated fatty acid (SFA), C20:3n-6, serum alanine aminotransferase, high-density lipoprotein cholesterol, and body mass index were independent risk factors of NAFLD. The risk of NAFLD was significantly increased with higher quartiles of plasma PL total SFA (P for trend = 0.028) and C20:3n-6 (P for trend <0.001); plasma PL docosahexaenoic acid (C22:6n-3) was significantly lower in NAFLD patients than in controls (P = 0.032) and the OR of NAFLD in the highest quartile of C22:6n-3 was 0.41 (95 % CI = 0.17-0.97) compared with the lowest quartile. In conclusion, plasma PL total SFA and C20:3n-6 are positively correlated with the risk of NAFLD, while C22:6n-3 is negatively correlated with the risk of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22527845     DOI: 10.1007/s11745-012-3671-4

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  42 in total

1.  A case-control study on nutritional risk factors in non-alcoholic fatty liver disease in Indian population.

Authors:  E Sathiaraj; M Chutke; M Y Reddy; N Pratap; P N Rao; D N Reddy; M Raghunath
Journal:  Eur J Clin Nutr       Date:  2011-02-23       Impact factor: 4.016

2.  Fatty liver and the metabolic syndrome among Shanghai adults.

Authors:  Jian-Gao Fan; June Zhu; Xing-Jian Li; Lan Chen; Yuan-San Lu; Lui Li; Fei Dai; Feng Li; Shi-Yao Chen
Journal:  J Gastroenterol Hepatol       Date:  2005-12       Impact factor: 4.029

3.  Regulatory effects of the saturated fatty acids 6:0 through 18:0 on hepatic low density lipoprotein receptor activity in the hamster.

Authors:  L A Woollett; D K Spady; J M Dietschy
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

4.  Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.

Authors:  Francesco Sofi; Ilaria Giangrandi; Francesca Cesari; Ilaria Corsani; Rosanna Abbate; Gian Franco Gensini; Alessandro Casini
Journal:  Int J Food Sci Nutr       Date:  2010-05-13       Impact factor: 3.833

5.  Effects on plasma lipids and fatty acid composition of very low fat diets enriched with fish or kangaroo meat.

Authors:  A J Sinclair; K O'Dea; G Dunstan; P D Ireland; M Niall
Journal:  Lipids       Date:  1987-07       Impact factor: 1.880

6.  Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study.

Authors:  Shira Zelber-Sagi; Dorit Nitzan-Kaluski; Rebecca Goldsmith; Muriel Webb; Laurie Blendis; Zamir Halpern; Ran Oren
Journal:  J Hepatol       Date:  2007-08-14       Impact factor: 25.083

Review 7.  Epidemiology of non-alcoholic fatty liver disease in China.

Authors:  Jian-Gao Fan; Geoffrey C Farrell
Journal:  J Hepatol       Date:  2008-11-06       Impact factor: 25.083

8.  Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.

Authors:  Wolfram Goessling; Joseph M Massaro; Ramachandran S Vasan; Ralph B D'Agostino; R Curtis Ellison; Caroline S Fox
Journal:  Gastroenterology       Date:  2008-09-20       Impact factor: 22.682

9.  Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.

Authors:  Deepa Uchil; D Pipalia; M Chawla; R Patel; Sonali Maniar; Archana Juneja
Journal:  J Assoc Physicians India       Date:  2009-03

10.  Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease.

Authors:  L Spadaro; O Magliocco; D Spampinato; S Piro; C Oliveri; C Alagona; G Papa; A M Rabuazzo; F Purrello
Journal:  Dig Liver Dis       Date:  2007-12-04       Impact factor: 4.088

View more
  11 in total

Review 1.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

2.  Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy; Kelli A Lytle
Journal:  Proc Nutr Soc       Date:  2015-08-18       Impact factor: 6.297

Review 3.  Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy; Kelli A Lytle
Journal:  Adv Nutr       Date:  2015-11-13       Impact factor: 8.701

Review 4.  Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease.

Authors:  Tannaz Eslamparast; Puneeta Tandon; Maitreyi Raman
Journal:  Nutrients       Date:  2017-07-26       Impact factor: 5.717

5.  Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.

Authors:  Kelli A Lytle; Carmen P Wong; Donald B Jump
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

6.  Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease.

Authors:  Kathy Musa-Veloso; Carolina Venditti; Han Youl Lee; Maryse Darch; Seth Floyd; Spencer West; Ryan Simon
Journal:  Nutr Rev       Date:  2018-08-01       Impact factor: 7.110

Review 7.  Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics.

Authors:  Anna Di Sessa; Simona Riccio; Emilia Pirozzi; Martina Verde; Antonio Paride Passaro; Giuseppina Rosaria Umano; Stefano Guarino; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

8.  Brain docosahexaenoic acid [DHA] incorporation and blood flow are increased in chronic alcoholics: a positron emission tomography study corrected for cerebral atrophy.

Authors:  John C Umhau; Weiyin Zhou; Shantalaxmi Thada; James Demar; Nahed Hussein; Abesh K Bhattacharjee; Kaizong Ma; Sharon Majchrzak-Hong; Peter Herscovitch; Norman Salem; Abigail Urish; Joseph R Hibbeln; Stephen C Cunnane; Stanley I Rapoport; Jussi Hirvonen
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

Review 9.  Lipidomics in non-alcoholic fatty liver disease.

Authors:  Sofia Kartsoli; Christina E Kostara; Vasilis Tsimihodimos; Eleni T Bairaktari; Dimitrios K Christodoulou
Journal:  World J Hepatol       Date:  2020-08-27

10.  A Lipidomic Analysis of Docosahexaenoic Acid (22:6, ω3) Mediated Attenuation of Western Diet Induced Nonalcoholic Steatohepatitis in Male Ldlr -/- Mice.

Authors:  Manuel García-Jaramillo; Kelli A Lytle; Melinda H Spooner; Donald B Jump
Journal:  Metabolites       Date:  2019-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.